Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome.
Description | Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome. |
Synonyms | inhibit, asthma, cystic fibrosis, Talniflumate, Inhibitor, pulmonary, obstructive, Chloride Channel, anti-inflammatory, BA 7602-06, Somalgen, COPD, Cl? Channels, chronic, ulcerogenic, Intestinal disease, analgesic |
Molecular Weight | 414.34 |
Formula | C21H13F3N2O4 |
CAS No. | 66898-62-2 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 10 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.